Histone lactylation moves into Alzheimer’s disease biology
Alzheimer’s disease remains a progressive neurodegenerative disorder defined by insidious cognitive decline and the accumulation of amyloid-β plaques and neurofibrillary tangles. The burden is rising with population aging, yet the molecular logic of the disease still resists a single unifying explanation. In that setting, a 2025 narrative review in Journal of Inflammation Research places histone lactylation among the epigenetic mechanisms now under scrutiny for its possible role in disease initiation and progression.
Lactylation is a metabolite-derived post-translational modification in which lactate groups are covalently attached to lysine residues. In practical terms, it links cellular metabolism to gene regulation, creating a route by which inflammatory stress and altered glycolysis can reshape transcriptional programs inside the brain. The review centers on how that mechanism may intersect with neuroinflammation, microglial activation, amyloid processing, and pyroptotic cell death.
One sentence captures the shift plainly: metabolic byproducts are no longer being treated as passive debris.
Glycolysis, microglia, and the H4K12la feedback loop
Among the most concrete mechanisms discussed is lactylation at histone H4 lysine 12, or H4K12la. The review describes evidence that this mark can promote neuroinflammation through a “glycolysis/H4K12la/PKM2” positive feedback loop. In that schema, glycolytic activity increases lactate availability, lactate promotes histone lactylation, and the resulting transcriptional changes reinforce glycolysis through PKM2-related signaling. The loop matters because inflammatory cells in the central nervous system, especially microglia, can be driven toward sustained activation when energy metabolism and gene expression begin amplifying one another.
That biological pattern is important in Alzheimer’s disease because microglial activation is not merely a bystander finding. Activated microglia can contribute to inflammatory injury, propagate cytokine release, and help shape the local plaque environment. A lactylation-driven feed-forward circuit offers a plausible explanation for why inflammatory signaling can become self-sustaining in the diseased brain, even when the original trigger is no longer obvious.
The review also links H4K12la to activation of the NLRP3 inflammasome and downstream pyroptosis. Pyroptosis is a highly inflammatory form of programmed cell death, and its engagement in the central nervous system would be expected to worsen tissue injury rather than resolve it. By connecting lactylation to inflammasome biology, the article places this epigenetic modification squarely inside the inflammatory machinery that has already become central to Alzheimer’s research.
H3K18la and the NF-κB axis in glial activation
A second epigenetic mark receives similar attention: H3K18la. Here, the review describes a pathway in which histone lactylation may enhance microglial activation through the NF-κB signaling axis. NF-κB is a familiar transcriptional hub in inflammatory biology, and its involvement gives the lactylation hypothesis a degree of mechanistic coherence. If lactylation strengthens NF-κB-driven inflammatory transcription, then the modification is not an isolated epiphenomenon; it becomes part of the machinery translating metabolic stress into sustained glial activation.
This matters at the bedside because Alzheimer’s disease does not unfold as a single lesion. It emerges from the interaction of protein aggregation, immune activation, synaptic dysfunction, and neuronal vulnerability. An epigenetic mechanism that can influence inflammatory transcription across those domains could help explain why the disease remains so biologically heterogeneous and why no single therapeutic pathway has yet solved it.
Amyloid-β biology remains less straightforward
The review is careful on a point that should not be flattened into certainty: the relationship between lactylation and Aβ pathology appears context-dependent. Findings are described as seemingly contradictory, which is not a weakness of the field so much as a sign that lactylation may behave differently depending on cell type, timing, or local inflammatory state. In one setting, the modification may intensify pathogenic signaling; in another, it may participate in compensatory or compensative responses that are not immediately harmful.
That ambiguity is biologically plausible. Histone modifications rarely act as on-off switches, especially in a disease as temporally complex as Alzheimer’s. The same metabolite signal that marks inflammatory activation in microglia may influence transcriptional networks differently in neurons, astrocytes, or other brain-resident cells. Without cell-specific and stage-specific data, any attempt to assign lactylation a single directional effect on amyloid biology would be premature.
Why this epigenetic pathway drew attention
The appeal of the lactylation hypothesis is that it bridges several layers of Alzheimer’s pathophysiology at once. It ties altered metabolism to chromatin remodeling, chromatin remodeling to transcription, and transcription to inflammatory output. That is a coherent way to think about a disease in which metabolic stress, immune activation, and protein aggregation are already known to overlap. The review’s value lies in assembling these threads into a single conceptual framework rather than treating each one as an isolated curiosity.
Histone lactylation may also provide a candidate marker for disease-related cellular states. If specific lactylation patterns track with microglial activation or neuroinflammatory burden, they could eventually support biomarker work or help define therapeutic windows. For now, though, the article stays within the bounds of theory and literature synthesis. It does not claim a validated clinical assay or a ready-made treatment.
Therapeutic implications remain speculative but biologically grounded
Any attempt to target lactylation therapeutically would need to confront a difficult reality: the same modification may be involved in both adaptive and maladaptive responses. Blunting lactylation indiscriminately could interfere with essential metabolic signaling, while selective modulation would require a far more detailed map of the enzymes, substrates, and cellular contexts involved. The review therefore reads less like a treatment proposal than a research agenda.
Still, the conceptual payoff is substantial. A mechanism that links glycolysis, H4K12la, H3K18la, NF-κB, and the NLRP3 inflammasome gives investigators a defined route from metabolism to inflammation in the Alzheimer’s brain. It also reframes epigenetic regulation as a dynamic response to metabolic stress rather than a static layer of gene control. For a disorder as complex as Alzheimer’s disease, that kind of mechanistic bridge may prove more useful than any single biomarker claim.
The review ends where the field itself now stands: with strong biological rationale, incomplete causal mapping, and no settled answer on how lactylation shapes amyloid pathology across disease stages. The next step is not a broader summary of the problem, but experimental work that can separate cell type, timing, and directionality before any therapeutic promise is assigned.